Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 4/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926531 | 0.80 | ANO1 (0.51) | P2RX7HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9926646 | 0.77 | P2RX7 (0.48) | P2RX7KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL9926578 | 0.76 | P2RX7 (0.41) | P2RX7KMT2A | |
| SCHEMBL9926464 | 0.76 | P2RX7 (0.51) | P2RX7HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL8651252 | 0.76 | SHMT1 (0.55) | P2RX7HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9926520 | 0.75 | MEN1 (0.55) | P2RX7KMT2AERCC1ERCC4NPC1 | |
| SCHEMBL8651766 | 0.74 | P2RX7 (0.47) | P2RX7HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL8651253 | 0.74 | P2RX7 (0.50) | P2RX7KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL9926585 | 0.74 | P2RX7 (0.50) | P2RX7KMT2AALDH1A1 | |
| SCHEMBL9926533 | 0.73 | SMN1; SMN2 (0.66) | P2RX7KMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | P2RX7 3259/4885KMT2A 1512/4885CNR1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.